Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1998 Feb;51(1):1–7. doi: 10.1136/mp.51.1.1

Cyclin D1 and human neoplasia.

R Donnellan 1, R Chetty 1
PMCID: PMC395600  PMID: 9624412

Abstract

Neoplasia is characterised by abnormal regulation of the cell cycle. Cyclin D1 is a protein derived from the PRAD1, CCND1 or bcl-1 gene on chromosome 11q13, which is involved in both normal regulation of the cell cycle and neoplasia. In the G1 (resting) phase of the cell cycle, cyclin D1 together with its cyclin dependent kinase (cdk) partner, is responsible for transition to the S (DNA synthesis) phase by phosphorylating the product of the retinoblastoma gene (pRB), which then releases transcription factors important in the initiation of DNA replication. Amplification of the CCND1 gene or overexpression of the cyclin D1 protein releases a cell from its normal controls and causes transformation to a malignant phenotype. Analysis of these changes provides important diagnostic information in mantle cell (and related) lymphomas, and is of prognostic value in many cancers. Knowledge of cyclin D1's role in malignancy at the various sites, provides a basis on which future treatment directed against this molecule can proceed.

Full Text

The Full Text of this article is available as a PDF (157.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnane J., Gaudray P., Simon M. P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene. 1989 Nov;4(11):1389–1395. [PubMed] [Google Scholar]
  2. Akervall J. A., Michalides R. J., Mineta H., Balm A., Borg A., Dictor M. R., Jin Y., Loftus B., Mertens F., Wennerberg J. P. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997 Jan 15;79(2):380–389. [PubMed] [Google Scholar]
  3. Arber N., Doki Y., Han E. K., Sgambato A., Zhou P., Kim N. H., Delohery T., Klein M. G., Holt P. R., Weinstein I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997 Apr 15;57(8):1569–1574. [PubMed] [Google Scholar]
  4. Arber N., Hibshoosh H., Moss S. F., Sutter T., Zhang Y., Begg M., Wang S., Weinstein I. B., Holt P. R. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996 Mar;110(3):669–674. doi: 10.1053/gast.1996.v110.pm8608874. [DOI] [PubMed] [Google Scholar]
  5. Banks P. M., Chan J., Cleary M. L., Delsol G., De Wolf-Peeters C., Gatter K., Grogan T. M., Harris N. L., Isaacson P. G., Jaffe E. S. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992 Jul;16(7):637–640. doi: 10.1097/00000478-199207000-00001. [DOI] [PubMed] [Google Scholar]
  6. Banno S., Yoshikawa K., Nakamura S., Yamamoto K., Seito T., Nitta M., Takahashi T., Ueda R., Seto M. Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. Jpn J Cancer Res. 1994 Sep;85(9):918–926. doi: 10.1111/j.1349-7006.1994.tb02969.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barbareschi M., Pelosio P., Caffo O., Buttitta F., Pellegrini S., Barbazza R., Dalla Palma P., Bevilacqua G., Marchetti A. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer. 1997 Apr 22;74(2):171–174. doi: 10.1002/(sici)1097-0215(19970422)74:2<171::aid-ijc5>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  8. Barbieri F., Cagnoli M., Ragni N., Pedullà F., Foglia G., Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer. 1997;75(9):1263–1268. doi: 10.1038/bjc.1997.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Barnes D. M. Cyclin D1 in mammary carcinoma. J Pathol. 1997 Mar;181(3):267–269. doi: 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  10. Bartkova J., Lukas J., Müller H., Lützhøft D., Strauss M., Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994 May 1;57(3):353–361. doi: 10.1002/ijc.2910570311. [DOI] [PubMed] [Google Scholar]
  11. Bartkova J., Lukas J., Müller H., Strauss M., Gusterson B., Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995 Feb 15;55(4):949–956. [PubMed] [Google Scholar]
  12. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 1995 Feb 16;10(4):775–778. [PubMed] [Google Scholar]
  13. Bates S., Parry D., Bonetta L., Vousden K., Dickson C., Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 1994 Jun;9(6):1633–1640. [PubMed] [Google Scholar]
  14. Berenson J. R., Koga H., Yang J., Pearl J., Holmes E. C., Figlin R. Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group. Oncogene. 1990 Sep;5(9):1343–1348. [PubMed] [Google Scholar]
  15. Berns E. M., Klijn J. G., van Staveren I. L., Portengen H., Noordegraaf E., Foekens J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28(2-3):697–700. doi: 10.1016/s0959-8049(05)80129-7. [DOI] [PubMed] [Google Scholar]
  16. Betticher D. C. Cyclin D1, another molecule of the year? Ann Oncol. 1996 Mar;7(3):223–225. doi: 10.1093/oxfordjournals.annonc.a010563. [DOI] [PubMed] [Google Scholar]
  17. Betticher D. C., Heighway J., Hasleton P. S., Altermatt H. J., Ryder W. D., Cerny T., Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996 Feb;73(3):294–300. doi: 10.1038/bjc.1996.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Betticher D. C., Heighway J., Thatcher N., Hasleton P. S. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75(12):1761–1768. doi: 10.1038/bjc.1997.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Boggild M. D., Jenkinson S., Pistorello M., Boscaro M., Scanarini M., McTernan P., Perrett C. W., Thakker R. V., Clayton R. N. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab. 1994 Feb;78(2):387–392. doi: 10.1210/jcem.78.2.8106627. [DOI] [PubMed] [Google Scholar]
  20. Borg A., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Olsson H., Killander D., McGurie W. L. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer. 1991 Jan;63(1):136–142. doi: 10.1038/bjc.1991.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Buchkovich K., Duffy L. A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell. 1989 Sep 22;58(6):1097–1105. doi: 10.1016/0092-8674(89)90508-4. [DOI] [PubMed] [Google Scholar]
  22. Buckley M. F., Sweeney K. J., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., deFazio A., Watts C. K., Musgrove E. A., Sutherland R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993 Aug;8(8):2127–2133. [PubMed] [Google Scholar]
  23. Callender T., el-Naggar A. K., Lee M. S., Frankenthaler R., Luna M. A., Batsakis J. G. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994 Jul 1;74(1):152–158. doi: 10.1002/1097-0142(19940701)74:1<152::aid-cncr2820740124>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  24. Chellappan S. P., Hiebert S., Mudryj M., Horowitz J. M., Nevins J. R. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991 Jun 14;65(6):1053–1061. doi: 10.1016/0092-8674(91)90557-f. [DOI] [PubMed] [Google Scholar]
  25. Chen P. L., Scully P., Shew J. Y., Wang J. Y., Lee W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989 Sep 22;58(6):1193–1198. doi: 10.1016/0092-8674(89)90517-5. [DOI] [PubMed] [Google Scholar]
  26. Chetty R., Chetty S. Cyclin D1 and retinoblastoma protein expression in oesophageal squamous cell carcinoma. Mol Pathol. 1997 Oct;50(5):257–260. doi: 10.1136/mp.50.5.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Clayton R. N., Boggild M., Bates A. S., Bicknell J., Simpson D., Farrell W. Tumour suppressor genes in the pathogenesis of human pituitary tumours. Horm Res. 1997;47(4-6):185–193. doi: 10.1159/000185463. [DOI] [PubMed] [Google Scholar]
  28. Clurman B. E., Roberts J. M. Cell cycle and cancer. J Natl Cancer Inst. 1995 Oct 18;87(20):1499–1501. doi: 10.1093/jnci/87.20.1499. [DOI] [PubMed] [Google Scholar]
  29. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995 Sep;147(3):545–560. [PMC free article] [PubMed] [Google Scholar]
  30. Courjal F., Louason G., Speiser P., Katsaros D., Zeillinger R., Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996 Aug 22;69(4):247–253. doi: 10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  31. DeCaprio J. A., Ludlow J. W., Lynch D., Furukawa Y., Griffin J., Piwnica-Worms H., Huang C. M., Livingston D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 1989 Sep 22;58(6):1085–1095. doi: 10.1016/0092-8674(89)90507-2. [DOI] [PubMed] [Google Scholar]
  32. Dees C., Foster J. S., Ahamed S., Wimalasena J. Dietary estrogens stimulate human breast cells to enter the cell cycle. Environ Health Perspect. 1997 Apr;105 (Suppl 3):633–636. doi: 10.1289/ehp.97105s3633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Defeo-Jones D., Huang P. S., Jones R. E., Haskell K. M., Vuocolo G. A., Hanobik M. G., Huber H. E., Oliff A. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature. 1991 Jul 18;352(6332):251–254. doi: 10.1038/352251a0. [DOI] [PubMed] [Google Scholar]
  34. Dirks P. B., Hubbard S. L., Murakami M., Rutka J. T. Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol. 1997 Mar;56(3):291–300. doi: 10.1097/00005072-199703000-00008. [DOI] [PubMed] [Google Scholar]
  35. Dowdy S. F., Hinds P. W., Louie K., Reed S. I., Arnold A., Weinberg R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 1993 May 7;73(3):499–511. doi: 10.1016/0092-8674(93)90137-f. [DOI] [PubMed] [Google Scholar]
  36. Downward J. Cell cycle: routine role for Ras. Curr Biol. 1997 Apr 1;7(4):R258–R260. doi: 10.1016/s0960-9822(06)00116-3. [DOI] [PubMed] [Google Scholar]
  37. Ewen M. E., Sluss H. K., Sherr C. J., Matsushime H., Kato J., Livingston D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993 May 7;73(3):487–497. doi: 10.1016/0092-8674(93)90136-e. [DOI] [PubMed] [Google Scholar]
  38. Fantl V., Richards M. A., Smith R., Lammie G. A., Johnstone G., Allen D., Gregory W., Peters G., Dickson C., Barnes D. M. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer. 1990 Apr;26(4):423–429. doi: 10.1016/0277-5379(90)90009-i. [DOI] [PubMed] [Google Scholar]
  39. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995 Oct 1;9(19):2364–2372. doi: 10.1101/gad.9.19.2364. [DOI] [PubMed] [Google Scholar]
  40. Fracchiolla N. S., Pruneri G., Pignataro L., Carboni N., Capaccio P., Boletini A., Buffa R., Neri A. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer. 1997 Mar 15;79(6):1114–1121. [PubMed] [Google Scholar]
  41. Friend S. H., Horowitz J. M., Gerber M. R., Wang X. F., Bogenmann E., Li F. P., Weinberg R. A. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9059–9063. doi: 10.1073/pnas.84.24.9059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Frierson H. F., Jr, Gaffey M. J., Zukerberg L. R., Arnold A., Williams M. E. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol. 1996 Jul;9(7):725–730. [PubMed] [Google Scholar]
  43. Fung Y. K., Murphree A. L., T'Ang A., Qian J., Hinrichs S. H., Benedict W. F. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 1987 Jun 26;236(4809):1657–1661. doi: 10.1126/science.2885916. [DOI] [PubMed] [Google Scholar]
  44. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., Beger H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997 May 1;57(9):1634–1637. [PubMed] [Google Scholar]
  45. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994 Apr 1;54(7):1812–1817. [PubMed] [Google Scholar]
  46. Gillett C., Smith P., Gregory W., Richards M., Millis R., Peters G., Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996 Apr 22;69(2):92–99. doi: 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  47. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. doi: 10.1016/s0065-230x(08)60352-8. [DOI] [PubMed] [Google Scholar]
  48. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361–1392. [PubMed] [Google Scholar]
  49. Hatada I., Tokino T., Ochiya T., Matsubara K. Co-amplification of integrated hepatitis B virus DNA and transforming gene hst-1 in a hepatocellular carcinoma. Oncogene. 1988 Nov;3(5):537–540. [PubMed] [Google Scholar]
  50. Hayashi T., Ohno H., Yamabe H., Nasu K., Miyaoka K., Fujii H., Akaogi T., Konishi H., Maseki N., Akasaka T. Clinical aspects of B-cell malignancy involving the BCL1/PRAD1 locus. Int J Hematol. 1994 Jun;59(4):281–296. [PubMed] [Google Scholar]
  51. He J., Allen J. R., Collins V. P., Allalunis-Turner M. J., Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804–5807. [PubMed] [Google Scholar]
  52. Hinds P. W., Mittnacht S., Dulic V., Arnold A., Reed S. I., Weinberg R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992 Sep 18;70(6):993–1006. doi: 10.1016/0092-8674(92)90249-c. [DOI] [PubMed] [Google Scholar]
  53. Hinds P. W., Weinberg R. A. Tumor suppressor genes. Curr Opin Genet Dev. 1994 Feb;4(1):135–141. doi: 10.1016/0959-437x(94)90102-3. [DOI] [PubMed] [Google Scholar]
  54. Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995 Aug 1;86(3):841–854. [PubMed] [Google Scholar]
  55. Hsi E. D., Zukerberg L. R., Yang W. I., Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996 May;81(5):1736–1739. doi: 10.1210/jcem.81.5.8626826. [DOI] [PubMed] [Google Scholar]
  56. Hung W. C., Chai C. Y., Huang J. S., Chuang L. Y. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol. 1996 Dec;27(12):1324–1328. doi: 10.1016/s0046-8177(96)90345-7. [DOI] [PubMed] [Google Scholar]
  57. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  58. Inohara S., Kitagawa K., Kitano Y. Expression of cyclin D1 and p53 protein in various malignant skin tumors. Dermatology. 1996;192(2):94–98. doi: 10.1159/000246329. [DOI] [PubMed] [Google Scholar]
  59. Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 1992 May 15;52(10):2980–2983. [PubMed] [Google Scholar]
  60. Jiang W., Kahn S. M., Zhou P., Zhang Y. J., Cacace A. M., Infante A. S., Doi S., Santella R. M., Weinstein I. B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993 Dec;8(12):3447–3457. [PubMed] [Google Scholar]
  61. Jiang W., Zhang Y. J., Kahn S. M., Hollstein M. C., Santella R. M., Lu S. H., Harris C. C., Montesano R., Weinstein I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9026–9030. doi: 10.1073/pnas.90.19.9026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Kaelin W. G., Jr, Pallas D. C., DeCaprio J. A., Kaye F. J., Livingston D. M. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell. 1991 Feb 8;64(3):521–532. doi: 10.1016/0092-8674(91)90236-r. [DOI] [PubMed] [Google Scholar]
  63. Kato J., Matsushime H., Hiebert S. W., Ewen M. E., Sherr C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993 Mar;7(3):331–342. doi: 10.1101/gad.7.3.331. [DOI] [PubMed] [Google Scholar]
  64. Kitagawa Y., Ueda M., Ando N., Shinozawa Y., Shimizu N., Abe O. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res. 1991 Mar 1;51(5):1504–1508. [PubMed] [Google Scholar]
  65. Kok K., van den Berg A., Veldhuis P. M., van der Veen A. Y., Franke M., Schoenmakers E. F., Hulsbeek M. M., van der Hout A. H., de Leij L., van de Ven W. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res. 1994 Aug 1;54(15):4183–4187. [PubMed] [Google Scholar]
  66. Kumar S., Krenacs L., Otsuki T., Kumar D., Harris C. A., Wellmann A., Jaffe E. S., Raffeld M. bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Am J Clin Pathol. 1996 Jun;105(6):737–743. doi: 10.1093/ajcp/105.6.737. [DOI] [PubMed] [Google Scholar]
  67. Kuroda H., Komatsu H., Nakamura S., Niitsu Y., Takahashi T., Ueda R., Seto M. The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Jpn J Cancer Res. 1995 Sep;86(9):890–898. doi: 10.1111/j.1349-7006.1995.tb03102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Kurzrock R., Ku S., Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer. 1995 Jan 15;75(2):584–590. doi: 10.1002/1097-0142(19950115)75:2<584::aid-cncr2820750223>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  69. Kwa H. B., Michalides R. J., Dijkman J. H., Mooi W. J. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer. 1996 Jun;14(2-3):207–217. doi: 10.1016/0169-5002(96)00547-8. [DOI] [PubMed] [Google Scholar]
  70. Lammie G. A., Fantl V., Smith R., Schuuring E., Brookes S., Michalides R., Dickson C., Arnold A., Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991 Mar;6(3):439–444. [PubMed] [Google Scholar]
  71. Latil A., Baron J. C., Cussenot O., Fournier G., Boccon-Gibod L., Le Duc A., Lidereau R. Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer. 1994 Dec 1;59(5):637–638. doi: 10.1002/ijc.2910590510. [DOI] [PubMed] [Google Scholar]
  72. Leach F. S., Elledge S. J., Sherr C. J., Willson J. K., Markowitz S., Kinzler K. W., Vogelstein B. Amplification of cyclin genes in colorectal carcinomas. Cancer Res. 1993 May 1;53(9):1986–1989. [PubMed] [Google Scholar]
  73. Lee C. C., Yamamoto S., Morimura K., Wanibuchi H., Nishisaka N., Ikemoto S., Nakatani T., Wada S., Kishimoto T., Fukushima S. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997 Feb 15;79(4):780–789. doi: 10.1002/(sici)1097-0142(19970215)79:4<780::aid-cncr15>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  74. Lee W. H., Shew J. Y., Hong F. D., Sery T. W., Donoso L. A., Young L. J., Bookstein R., Lee E. Y. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature. 1987 Oct 15;329(6140):642–645. doi: 10.1038/329642a0. [DOI] [PubMed] [Google Scholar]
  75. Ligueros M., Jeoung D., Tang B., Hochhauser D., Reidenberg M. M., Sonenberg M. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer. 1997;76(1):21–28. doi: 10.1038/bjc.1997.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Lukas J., Müller H., Bartkova J., Spitkovsky D., Kjerulff A. A., Jansen-Dürr P., Strauss M., Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol. 1994 May;125(3):625–638. doi: 10.1083/jcb.125.3.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Maeda K., Chung Y. S., Kang S. M., Ogawa M., Onoda N., Nakata B., Nishiguchi Y., Ikehara T., Okuno M., Sowa M. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer. 1997 Jun 20;74(3):310–315. doi: 10.1002/(sici)1097-0215(19970620)74:3<310::aid-ijc13>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  78. Maelandsmo G. M., Berner J. M., Flørenes V. A., Forus A., Hovig E., Fodstad O., Myklebost O. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer. 1995 Aug;72(2):393–398. doi: 10.1038/bjc.1995.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Masuda M., Hirakawa N., Nakashima T., Kuratomi Y., Komiyama S. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer. 1996 Aug 1;78(3):390–395. doi: 10.1002/(SICI)1097-0142(19960801)78:3<390::AID-CNCR2>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  80. Mate J. L., Ariza A., Aracil C., López D., Isamat M., Pérez-Piteira J., Navas-Palacios J. J. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol. 1996 Dec;180(4):395–399. doi: 10.1002/(SICI)1096-9896(199612)180:4<395::AID-PATH688>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  81. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry J. A., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed] [Google Scholar]
  82. Meeker T. C., Grimaldi J. C., O'Rourke R., Louie E., Juliusson G., Einhorn S. An additional breakpoint region in the BCL-1 locus associated with the t(11;14)(q13;q32) translocation of B-lymphocytic malignancy. Blood. 1989 Oct;74(5):1801–1806. [PubMed] [Google Scholar]
  83. Michalides R. J., van Veelen N. M., Kristel P. M., Hart A. A., Loftus B. M., Hilgers F. J., Balm A. J. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497–502. doi: 10.1001/archotol.1997.01900050045005. [DOI] [PubMed] [Google Scholar]
  84. Michalides R., Hageman P., van Tinteren H., Houben L., Wientjens E., Klompmaker R., Peterse J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996 Mar;73(6):728–734. doi: 10.1038/bjc.1996.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  86. Motokura T., Bloom T., Kim H. G., Jüppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512–515. doi: 10.1038/350512a0. [DOI] [PubMed] [Google Scholar]
  87. Müller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2945–2949. doi: 10.1073/pnas.91.8.2945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Naitoh H., Shibata J., Kawaguchi A., Kodama M., Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol. 1995 May;146(5):1161–1169. [PMC free article] [PubMed] [Google Scholar]
  89. Nakagawa H., Wang T. C., Zukerberg L., Odze R., Togawa K., May G. H., Wilson J., Rustgi A. K. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene. 1997 Mar 13;14(10):1185–1190. doi: 10.1038/sj.onc.1200937. [DOI] [PubMed] [Google Scholar]
  90. Nakamura S., Seto M., Banno S., Suzuki S., Koshikawa T., Kitoh K., Kagami Y., Ogura M., Yatabe Y., Kojima M. Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. Jpn J Cancer Res. 1994 Dec;85(12):1270–1279. doi: 10.1111/j.1349-7006.1994.tb02940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Nakamura S., Yatabe Y., Kuroda H., Ueda R., Takahashi T., Suchi T., Seto M. Immunostaining of PRAD1/cyclin D1 protein as a marker for the diagnosis of mantle cell lymphoma. Leukemia. 1997 Apr;11 (Suppl 3):536–537. [PubMed] [Google Scholar]
  92. Nakamura T., Tokino T., Nagaya T., Matsubara K. Microdeletion associated with the integration process of hepatitis B virus DNA. Nucleic Acids Res. 1988 Jun 10;16(11):4865–4873. doi: 10.1093/nar/16.11.4865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Nevins J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992 Oct 16;258(5081):424–429. doi: 10.1126/science.1411535. [DOI] [PubMed] [Google Scholar]
  94. Nichols G. E., Williams M. E., Gaffey M. J., Stoler M. H. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol. 1996 Apr;9(4):418–425. [PubMed] [Google Scholar]
  95. Nielsen N. H., Emdin S. O., Cajander J., Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 1997 Jan 23;14(3):295–304. doi: 10.1038/sj.onc.1200833. [DOI] [PubMed] [Google Scholar]
  96. Nikaido T., Li S. F., Shiozawa T., Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer. 1996 Sep 15;78(6):1248–1253. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  97. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994 Jun 15;54(12):3107–3110. [PubMed] [Google Scholar]
  98. Ohtsubo M., Roberts J. M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science. 1993 Mar 26;259(5103):1908–1912. doi: 10.1126/science.8384376. [DOI] [PubMed] [Google Scholar]
  99. Oka K., Ohno T., Kita K., Yamaguchi M., Takakura N., Nishii K., Miwa H., Shirakawa S. PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. Br J Haematol. 1994 Apr;86(4):786–791. doi: 10.1111/j.1365-2141.1994.tb04830.x. [DOI] [PubMed] [Google Scholar]
  100. Ott G., Kalla J., Ott M. M., Schryen B., Katzenberger T., Müller J. G., Müller-Hermelink H. K. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997 Feb 15;89(4):1421–1429. [PubMed] [Google Scholar]
  101. Park S. K., Kang S. K., Lee D. Y., Kang M. J., Kim S. H., Koh G. Y. Temporal expressions of cyclins and cyclin dependent kinases during renal development and compensatory growth. Kidney Int. 1997 Mar;51(3):762–769. doi: 10.1038/ki.1997.107. [DOI] [PubMed] [Google Scholar]
  102. Peeper D. S., Upton T. M., Ladha M. H., Neuman E., Zalvide J., Bernards R., DeCaprio J. A., Ewen M. E. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 1997 Mar 13;386(6621):177–181. doi: 10.1038/386177a0. [DOI] [PubMed] [Google Scholar]
  103. Pelosio P., Barbareschi M., Bonoldi E., Marchetti A., Verderio P., Caffo O., Bevilacqua P., Boracchi P., Buttitta F., Barbazza R. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol. 1996 Sep;7(7):695–703. doi: 10.1093/oxfordjournals.annonc.a010718. [DOI] [PubMed] [Google Scholar]
  104. Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci Suppl. 1994;18:89–96. doi: 10.1242/jcs.1994.supplement_18.13. [DOI] [PubMed] [Google Scholar]
  105. Proctor A. J., Coombs L. M., Cairns J. P., Knowles M. A. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991 May;6(5):789–795. [PubMed] [Google Scholar]
  106. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J. Y., Bar-Sagi D., Roussel M. F., Sherr C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993 Aug;7(8):1559–1571. doi: 10.1101/gad.7.8.1559. [DOI] [PubMed] [Google Scholar]
  107. Resnitzky D., Gossen M., Bujard H., Reed S. I. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 1994 Mar;14(3):1669–1679. doi: 10.1128/mcb.14.3.1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Rimokh R., Berger F., Bastard C., Klein B., French M., Archimbaud E., Rouault J. P., Santa Lucia B., Duret L., Vuillaume M. Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994 Jun 15;83(12):3689–3696. [PubMed] [Google Scholar]
  109. Rimokh R., Berger F., Delsol G., Charrin C., Berthéas M. F., Ffrench M., Garoscio M., Felman P., Coiffier B., Bryon P. A. Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood. 1993 Jun 1;81(11):3063–3067. [PubMed] [Google Scholar]
  110. Rogler C. E. Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. Curr Top Microbiol Immunol. 1991;168:103–140. doi: 10.1007/978-3-642-76015-0_6. [DOI] [PubMed] [Google Scholar]
  111. Rosenberg C. L., Motokura T., Kronenberg H. M., Arnold A. Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. Oncogene. 1993 Feb;8(2):519–521. [PubMed] [Google Scholar]
  112. Rosenberg C. L., Wong E., Petty E. M., Bale A. E., Tsujimoto Y., Harris N. L., Arnold A. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9638–9642. doi: 10.1073/pnas.88.21.9638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. Gene. 1995 Jun 14;159(1):83–96. doi: 10.1016/0378-1119(94)00562-7. [DOI] [PubMed] [Google Scholar]
  114. Schuuring E., Verhoeven E., Mooi W. J., Michalides R. J. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene. 1992 Feb;7(2):355–361. [PubMed] [Google Scholar]
  115. Schuuring E., Verhoeven E., van Tinteren H., Peterse J. L., Nunnink B., Thunnissen F. B., Devilee P., Cornelisse C. J., van de Vijver M. J., Mooi W. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992 Oct 1;52(19):5229–5234. [PubMed] [Google Scholar]
  116. Sherr C. J. G1 phase progression: cycling on cue. Cell. 1994 Nov 18;79(4):551–555. doi: 10.1016/0092-8674(94)90540-1. [DOI] [PubMed] [Google Scholar]
  117. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  118. Shin K. Y., Kong G., Kim W. S., Lee T. Y., Woo Y. N., Lee J. D. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75(12):1788–1792. doi: 10.1038/bjc.1997.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Shinozaki H., Ozawa S., Ando N., Tsuruta H., Terada M., Ueda M., Kitajima M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 1996 Jul;2(7):1155–1161. [PubMed] [Google Scholar]
  120. Sicinski P., Donaher J. L., Parker S. B., Li T., Fazeli A., Gardner H., Haslam S. Z., Bronson R. T., Elledge S. J., Weinberg R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995 Aug 25;82(4):621–630. doi: 10.1016/0092-8674(95)90034-9. [DOI] [PubMed] [Google Scholar]
  121. Silverstein M. J., Poller D. N., Waisman J. R., Colburn W. J., Barth A., Gierson E. D., Lewinsky B., Gamagami P., Slamon D. J. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995 May 6;345(8958):1154–1157. doi: 10.1016/s0140-6736(95)90982-6. [DOI] [PubMed] [Google Scholar]
  122. Simpson J. F., Quan D. E., O'Malley F., Odom-Maryon T., Clarke P. E. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997 Jul;151(1):161–168. [PMC free article] [PubMed] [Google Scholar]
  123. Swerdlow S. H., Yang W. I., Zukerberg L. R., Harris N. L., Arnold A., Williams M. E. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol. 1995 Sep;26(9):999–1004. doi: 10.1016/0046-8177(95)90090-x. [DOI] [PubMed] [Google Scholar]
  124. Tam S. W., Theodoras A. M., Shay J. W., Draetta G. F., Pagano M. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene. 1994 Sep;9(9):2663–2674. [PubMed] [Google Scholar]
  125. Tang R. P., Kacinski B., Validire P., Beuvon F., Sastre X., Benoit P., dela Rochefordière A., Mosseri V., Pouillart P., Scholl S. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem. 1990 Nov;44(3):189–198. doi: 10.1002/jcb.240440307. [DOI] [PubMed] [Google Scholar]
  126. Theillet C., Le Roy X., De Lapeyrière O., Grosgeorges J., Adnane J., Raynaud S. D., Simony-Lafontaine J., Goldfarb M., Escot C., Birnbaum D. Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas. Oncogene. 1989 Jul;4(7):915–922. [PubMed] [Google Scholar]
  127. Tsuda T., Nakatani H., Tahara E., Sakamoto H., Terada M., Sugimura T. HST1 and INT2 gene coamplification in a squamous cell carcinoma of the gallbladder. Jpn J Clin Oncol. 1989 Mar;19(1):26–29. [PubMed] [Google Scholar]
  128. Tsuda T., Tahara E., Kajiyama G., Sakamoto H., Terada M., Sugimura T. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res. 1989 Oct 15;49(20):5505–5508. [PubMed] [Google Scholar]
  129. Tsutsumi M., Sakamoto H., Yoshida T., Kakizoe T., Koiso K., Sugimura T., Terada M. Coamplification of the hst-1 and int-2 genes in human cancers. Jpn J Cancer Res. 1988 Apr;79(4):428–432. doi: 10.1111/j.1349-7006.1988.tb01609.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Vasef M. A., Medeiros L. J., Yospur L. S., Sun N. C., McCourty A., Brynes R. K. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol. 1997 Sep;10(9):927–932. [PubMed] [Google Scholar]
  131. Wakasugi E., Kobayashi T., Tamaki Y., Nakano Y., Ito Y., Miyashiro I., Komoike Y., Miyazaki M., Takeda T., Monden T. Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer. J Clin Pathol. 1997 May;50(5):407–412. doi: 10.1136/jcp.50.5.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Wang L. D., Shi S. T., Zhou Q., Goldstein S., Hong J. Y., Shao P., Qiu S. L., Yang C. S. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994 Nov 15;59(4):514–519. doi: 10.1002/ijc.2910590414. [DOI] [PubMed] [Google Scholar]
  133. Weinstat-Saslow D., Merino M. J., Manrow R. E., Lawrence J. A., Bluth R. F., Wittenbel K. D., Simpson J. F., Page D. L., Steeg P. S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995 Dec;1(12):1257–1260. doi: 10.1038/nm1295-1257. [DOI] [PubMed] [Google Scholar]
  134. Weinstein I. B. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem Suppl. 1996;25:23–28. [PubMed] [Google Scholar]
  135. Welcker M., Lukas J., Strauss M., Bartek J. Enhanced protein stability: a novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. Oncogene. 1996 Jul 18;13(2):419–425. [PubMed] [Google Scholar]
  136. Withers D. A., Harvey R. C., Faust J. B., Melnyk O., Carey K., Meeker T. C. Characterization of a candidate bcl-1 gene. Mol Cell Biol. 1991 Oct;11(10):4846–4853. doi: 10.1128/mcb.11.10.4846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Worsley S. D., Ponder B. A., Davies B. R. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol. 1997 Feb;64(2):189–195. doi: 10.1006/gyno.1996.4569. [DOI] [PubMed] [Google Scholar]
  138. Yang W. I., Chung K. Y., Shin D. H., Kim Y. B. Cyclin D1 protein expression in lung cancer. Yonsei Med J. 1996 Apr;37(2):142–150. doi: 10.3349/ymj.1996.37.2.142. [DOI] [PubMed] [Google Scholar]
  139. Zhang S. Y., Caamano J., Cooper F., Guo X., Klein-Szanto A. J. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994 Nov;102(5):695–698. doi: 10.1093/ajcp/102.5.695. [DOI] [PubMed] [Google Scholar]
  140. Zhang S. Y., Liu S. C., Goodrow T., Morris R., Klein-Szanto A. J. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog. 1997 Mar;18(3):142–152. [PubMed] [Google Scholar]
  141. Zhang T., Nanney L. B., Luongo C., Lamps L., Heppner K. J., DuBois R. N., Beauchamp R. D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997 Jan 1;57(1):169–175. [PubMed] [Google Scholar]
  142. Zhang Y. J., Jiang W., Chen C. J., Lee C. S., Kahn S. M., Santella R. M., Weinstein I. B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993 Oct 29;196(2):1010–1016. doi: 10.1006/bbrc.1993.2350. [DOI] [PubMed] [Google Scholar]
  143. Zhou P., Jiang W., Zhang Y. J., Kahn S. M., Schieren I., Santella R. M., Weinstein I. B. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 1995 Aug 3;11(3):571–580. [PubMed] [Google Scholar]
  144. Zwijsen R. M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., Michalides R. J. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997 Feb 7;88(3):405–415. doi: 10.1016/s0092-8674(00)81879-6. [DOI] [PubMed] [Google Scholar]
  145. de Boer C. J., Schuuring E., Dreef E., Peters G., Bartek J., Kluin P. M., van Krieken J. H. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995 Oct 1;86(7):2715–2723. [PubMed] [Google Scholar]
  146. de Boer C. J., van Krieken J. H., Kluin-Nelemans H. C., Kluin P. M., Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995 May 4;10(9):1833–1840. [PubMed] [Google Scholar]
  147. van Diest P. J., Michalides R. J., Jannink L., van der Valk P., Peterse H. L., de Jong J. S., Meijer C. J., Baak J. P. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997 Feb;150(2):705–711. [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES